While oncology remains the largest segment, Cardiology has emerged as the fastest-growing application in the France Radiopharmaceuticals Market. This growth is propelled by the rising prevalence of cardiovascular diseases among France’s aging population and the introduction of next-generation tracers like Rubidium-82 and Copper-64. These tracers allow for high-resolution PET myocardial perfusion imaging (MPI), which provides a more accurate assessment of blood flow to the heart muscle than traditional stress tests.

The rapid expansion into cardiology is also supported by the decentralization of diagnostic centers. In 2026, specialized cardiac clinics are increasingly installing their own compact cyclotrons, allowing them to produce short-lived isotopes on-site. This reduces the logistical burden of transporting radioactive materials from central hubs and ensures that patients in rural areas have access to the same level of advanced cardiac imaging as those in major metropolitan areas like Paris or Lyon.

FAQ:

• Question: Why is cardiology growing so fast in this market?

• Answer: Innovations in molecular imaging and a high demand for non-invasive heart assessments in the elderly are driving this nearly 9% annual growth.